Merck KGaA (OTCMKTS:MKKGY) Lowered to Hold Rating by Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft cut shares of Merck KGaA (OTCMKTS:MKKGY) from a buy rating to a hold rating in a research report report published on Tuesday morning, Marketbeat reports.

Merck KGaA Stock Performance

OTCMKTS MKKGY opened at $28.93 on Tuesday. The stock has a market capitalization of $18.69 billion, a price-to-earnings ratio of 11.53, a PEG ratio of 6.05 and a beta of 0.96. The stock has a 50-day moving average of $28.85 and a 200 day moving average of $27.05. The company has a current ratio of 1.49, a quick ratio of 0.97 and a debt-to-equity ratio of 0.36. Merck KGaA has a twelve month low of $24.32 and a twelve month high of $31.00.

Merck KGaA (OTCMKTS:MKKGY) last posted its quarterly earnings data on Thursday, November 13th. The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.27. The business had revenue of $6.17 billion during the quarter, compared to analysts’ expectations of $6.08 billion. Merck KGaA had a return on equity of 10.07% and a net margin of 13.92%. Sell-side analysts anticipate that Merck KGaA will post 1.87 EPS for the current fiscal year.

About Merck KGaA

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.